Venture Life Group PLC Director/PDMR Shareholding (3561Z)
09 Gennaio 2020 - 5:28PM
UK Regulatory
TIDMVLG
RNS Number : 3561Z
Venture Life Group PLC
09 January 2020
9 January 2020
Venture Life Group plc
("Venture Life" or the "Group")
Director dealings
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the international
self-care market, announces that Sharon Collins, Chief Commercial
Officer, purchased 283,600 ordinary shares of 0.3 pence each in the
capital of the Company ("Ordinary Shares") at a price of 35.75
pence per share on 8 January 2020 and a further 71,020 Ordinary
Shares at a price of 35.12 pence per share on 9 January 2020.
Following these purchases, Sharon Collins is interested in
2,019,953 Ordinary Shares, representing approximately 2.41% of the
issued share capital of the Company.
For further information, please contact:
+44(0) 1344
Venture Life Group plc 578004
Jerry Randall, Chief Executive Officer
+44(0)20 7397
Cenkos Securities plc (Nomad and Broker) 8900
Mark Connelly / Stephen Keys / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
+44(0)20 3405
Alma PR 0205
Hilary Buchanan / Helena Bogle / Jessica Joynson
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for maintaining brain function, medical devices for
women's intimate healthcare and proctology and dermo-cosmetics for
addressing the signs of ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
The Company makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sharon Collins
------------------------ -----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Commercial Officer
------------------------ -----------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Venture Life Group plc
------------------------ -----------------------------------------
b) LEI 213800S8CZUPLAB2KC70
------------------------ -----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares of 0.3p each in Venture
of the financial Life Group plc
instrument,
type of instrument
------------------------ -----------------------------------------
b) Identification GB00BFPM8908
code
------------------------ -----------------------------------------
c) Nature of the Purchase of Ordinary Shares
transaction
------------------------ -----------------------------------------
d) Price and volumes Price Volume
1. GBP0.3575 1. 283,600
2. GBP0.3512 2. 71,020
----------------
------------------------ -----------------------------------------
d) Aggregated information
- Aggregated N/A - single trades
volume
- Price
------------------------ -----------------------------------------
e) Date of the 1. 8(th) January 2020
transaction
2. 9(th) January 2020
------------------------ -----------------------------------------
f) Place of the London Stock Exchange
transaction
------------------------ -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFLFFRLSIAIII
(END) Dow Jones Newswires
January 09, 2020 11:28 ET (16:28 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024